Prostatic Neoplasms

• EMA approval · 2026-08-06
  EMA Authorised: Docetaxel Kabi (docetaxel) — Fresenius Kabi Deutschland GmbH

  EU authorization of Docetaxel Kabi (docetaxel) for multiple cancer indications including head and neck neoplasms, non-small cell lung carcin…

• EMA approval · 2026-08-05
  EMA Authorised: Degarelix Accord (degarelix acetate) — Accord Healthcare S.L.U.

  Degarelix Accord (degarelix acetate) has been authorised by the EMA for prostatic neoplasms.

• EMA approval · 2026-07-30
  EMA Authorised: Xofigo (radium (223Ra) dichloride) — Bayer AG

  EMA authorises Xofigo (radium-223 dichloride) for therapeutic use in prostatic neoplasms.

• EMA approval · 2026-07-29
  EMA Authorised: Xtandi (enzalutamide) — Astellas Pharma Europe B.V.

  Xtandi (enzalutamide) has been authorised in the EU for prostatic neoplasms by Astellas Pharma Europe B.V.

• EMA approval · 2026-07-02
  EMA Authorised: Xtandi (enzalutamide) — Astellas Pharma Europe B.V.

  Authorisation granted for Xtandi (enzalutamide) by EMA for prostatic neoplasms.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2026-02-24
  EMA Authorised: Enzalutamide Viatris (enzalutamide) — Viatris Limited

  EMA authorised a generic version of enzalutamide (Enzalutamide Viatris) for prostatic neoplasms, with Viatris Limited as the marketing autho…

• EMA approval · 2023-11-08
  EMA Authorised: Degarelix Accord (degarelix acetate) — Accord Healthcare S.L.U.

  The EMA has authorised Degarelix Accord (degarelix acetate) for prostatic neoplasms, marking an approved drug in Europe.

• EMA approval · 2022-12-07
  EMA Authorised: Tookad (padeliporfin di-potassium) — STEBA Biotech S.A

  The EMA has authorised Tookad (padeliporfin di-potassium) for prostatic neoplasms, with STEBA Biotech S.A. as the marketing authorization ho…

• EMA approval · 2022-10-04
  EMA Authorised: Firmagon (degarelix) — Ferring Pharmaceuticals A/S

  EMA authorisation of Firmagon (degarelix) for prostatic neoplasms.